

**Freedom of Information Act 2000****The Royal Cornwall Hospitals NHS Trust Response to Information request****Date Request Received: 02 April 2024****FOI Ref No: 24187****Requested Information:**

I am analysing the usage of new biologic and targeted medications within dermatology and respiratory medicine. Could you please answer the following questions:

1) How many patients were treated in March 2024 (or latest available month) by the Dermatology department with the following drugs:

- Abrocitinib (Cibinqo)
- Baricitinib (Olmiant)
- Dupilumab (Dupixent)
- Lebrikizumab (Ebglyss)
- Omalizumab (Xolair)
- Tralokinumab (Adtralza)
- Upadacitinib (Rinvoq)

2) How many patients were treated in March 2024 (or latest available month) by the Respiratory Medicine departments with the following drugs:

- Benralizumab (Fasenra)
- Dupilumab (Dupixent)
- Mepolizumab (Nucala)
- Omalizumab (Xolair)
- Reslizumab (Cinqaero)
- Tezepelumab (Tezspire)

**Response:**

1) How many patients were treated in March 2024 (or latest available month) by the Dermatology department with the following drugs:

- 
- Abrocitinib (Cibinqo) 6
- Baricitinib (Olmiant) 0
- Dupilumab (Dupixent) 52
- Lebrikizumab (Ebglyss) 0
- Omalizumab (Xolair) 4

- Tralokinumab (Adtralza) 12
- Upadacitinib (Rinvoq) 0

2) How many patients were treated in March 2024 (or latest available month) by the Respiratory Medicine departments with the following drugs:

- Benralizumab (Fasenra) 0
- Dupilumab (Dupixent) 0
- Mepolizumab (Nucala) 0
- Omalizumab (Xolair) 1
- Reslizumab (Cinqaero) 0
- Tezepelumab (Tezspire) 0

**Attachment(s):**

None

**Date Response sent:**